Pacific Edge (PEB) Investor update summary

Value Creation, Product Innovation, and Market Positioning

• Patented, non-invasive Cxbladder urine tests, including Triage Plus and Surveillance Plus, offer clinical, economic, and patient value, with Triage Plus priced at US$1,328/test and Surveillance Plus targeting US$1,800/test, supported by robust clinical evidence and a Grade A AUA rating for Triage.

• Cxbladder Triage is included in American Urological Association guidelines, supported by over 25 peer-reviewed publications and more than 30 total publications.

• Over 130,000 patients and 5,000+ urologists have used Cxbladder, with availability in the US, Australasia, Israel, and other global markets.

• Ongoing and planned studies aim to further strengthen clinical evidence and drive adoption.

Market Opportunity and Commercial Pathway

• The global addressable market for bladder cancer diagnostics is estimated at US$10.8 billion, with the US as the largest opportunity due to higher CMS pricing and a large hematuria patient population.

• Medicare re-coverage is a key catalyst, with a draft LCD for Triage and Triage Plus expected before September 2026 and final coverage before March 2027, unlocking commercial payer revenue.

• Novitas is expected to release a draft Local Coverage Determination for hematuria evaluation, potentially restoring Medicare coverage and enabling claim-by-claim reimbursement.

• Commercial payers cover nearly four times more lives than Medicare, and recent policy wins with BCBS North Carolina and South Carolina signal growing adoption.

Financial Performance and Cost Management

• FY26 operating revenue fell 47.4% to $11.5 million due to Medicare non-coverage and lower US test volumes.

• Net loss after tax increased to $35.7 million, while total expenses reduced to $49.3 million from $54.6 million, and monthly cash burn was reduced by 27.7% in 2H26 to $2.4 million.

• Cash and cash equivalents were $5.1 million at 30 April 2026 and $7.8 million at March 2026, with a $24 million capital raise underway to strengthen the balance sheet.